Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

Leukemia & Lymphoma
J R Brown

Abstract

The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lenalidomide in CLL therapy remains intense, however, and combination studies are in progress. As laboratory efforts start to provide more insight into the mechanisms of antitumor efficacy and tumor flare, rational strategies for combination therapy will soon follow.

References

Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanMyron S Czuczman
Nov 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laure A Moutouh-de ParsevalJerome B Zeldis
Apr 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leslie A AndritsosJohn C Byrd
Jan 9, 2010·Leukemia & Lymphoma·Taimur SherAsher Alban Chanan-Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.